IL5 and eosinophilic granulomatosis with polyangiitis: ,25 Other biologics under investigation for the treatment of EGPA include reslizumab (which also targets the IL-5 pathway), omalizumab (targeting IgE), tezepelumab (targeting thymic stromal lymphopoietin), and dupilumab (targeting IL-4/IL-13 signaling).23